A Phase II Study of Sorafenib (BAY 43-9006) in Patients With Relapsed Advanced Non-Small Cell Lung Cancer(NSCLC) After Failure of Epidermal Growth Factor Receptor-Tyrosine Kinase Inhibitor (EGFR-TKI)Treatment.

Trial Profile

A Phase II Study of Sorafenib (BAY 43-9006) in Patients With Relapsed Advanced Non-Small Cell Lung Cancer(NSCLC) After Failure of Epidermal Growth Factor Receptor-Tyrosine Kinase Inhibitor (EGFR-TKI)Treatment.

Completed
Phase of Trial: Phase II

Latest Information Update: 01 Mar 2014

At a glance

  • Drugs Sorafenib (Primary)
  • Indications Non-small cell lung cancer
  • Focus Therapeutic Use
  • Most Recent Events

    • 28 May 2012 Planned end date changed from 1 Jun 2010 to 1 Apr 2012 as reported by ClinicalTrials.gov.
    • 28 May 2012 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
    • 23 Jun 2009 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top